Michael Ehlers
Neuroscience Chief Scientific Officer
Pfizer
From this contributor
A cautionary tale for autism drug development
Poorly designed animal drug studies for motor disorders have led to spurious conclusions for the clinical trials that follow. This may be even more true for autism research, says Michael Ehlers.
SHANK mutations converge at neuronal junctions in autism
SHANK3, one of the strongest candidate genes for autism, has the potential to be a molecular entry point into understanding the synaptic, developmental and circuit origins of the disorder.
SHANK mutations converge at neuronal junctions in autism
Drug zone
Rodent and stem cell models remain challenging for developing psychiatric drugs, says Michael Ehlers, chief scientific officer of neuroscience at Pfizer.
Explore more from The Transmitter
Learning why spiny mice play well with others
Aubrey Kelly studies the gregarious mammal to explore how the brain controls complex social behaviors “akin to friendship.”
Learning why spiny mice play well with others
Aubrey Kelly studies the gregarious mammal to explore how the brain controls complex social behaviors “akin to friendship.”
Autism-linked genes expressed in thalamus make an impact, and more
Here is a roundup of autism-related news and research spotted around the web for the week of 1 June.
Autism-linked genes expressed in thalamus make an impact, and more
Here is a roundup of autism-related news and research spotted around the web for the week of 1 June.
Eighteen teams analyzed the same neurophysiology dataset—and got wildly different answers
The “Brainhack” hackathon revealed that disagreement in neuroscience runs deeper than most researchers suspect—even in electrophysiology, a field that prides itself on hard data.
Eighteen teams analyzed the same neurophysiology dataset—and got wildly different answers
The “Brainhack” hackathon revealed that disagreement in neuroscience runs deeper than most researchers suspect—even in electrophysiology, a field that prides itself on hard data.